Killa Acne Extra Strength 2 Pack

Description

The drug is identified by the SPL code 34089-3. It is presented as a white to off-white, round, biconvex tablet, which is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the management of acne. It penetrates pores to eliminate most blemishes, providing effective treatment for individuals experiencing this condition.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleansed prior to the application of KILLA ACNE Extra Strength pimple patch. Once the skin is dry, the patch should be applied directly onto the affected area. For optimal results, it is recommended to leave the patch on for a minimum of 2 hours to allow the microdarts to dissolve; however, leaving the patch on overnight is advised for enhanced efficacy.

The product is intended for topical application only.

Contraindications

Use is contraindicated in children due to the risk of accidental ingestion. In the event of swallowing, immediate medical assistance should be sought or contact with a poison control center is advised.

Warnings and Precautions

For external use only. It is imperative to keep this product out of the reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

Healthcare professionals should advise patients to consult a physician if any irritation becomes severe. Monitoring for signs of irritation is recommended to ensure patient safety and appropriate management of any adverse reactions.

Side Effects

For external use only. Patients should be advised to seek medical attention if irritation becomes severe.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Killa Acne Extra Strength 2 Pack (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a poison control center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of this product during pregnancy has not been established. Pregnant patients or those planning to become pregnant should consult a healthcare provider before use. The potential risks associated with the use of salicylic acid during pregnancy are not fully known; therefore, caution is advised. There are no specific dosage modifications for pregnant individuals provided in the prescribing information; personalized advice from a healthcare provider is recommended.

Lactation

There are no specific warnings or recommendations regarding nursing mothers or lactation in the provided text. Therefore, healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication. It is advisable to monitor breastfed infants for any potential effects, although no specific information is available.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider the potential risks associated with excessive administration of the medication.

It is essential to monitor patients closely for any signs or symptoms that may arise from an overdose. Symptoms may vary depending on the medication's pharmacological profile and the individual patient's response.

In the event of suspected overdosage, immediate medical intervention is recommended. Healthcare providers should initiate supportive care and symptomatic treatment as necessary. Additionally, contacting a poison control center or seeking guidance from a medical toxicologist may be beneficial in managing the situation effectively.

Documentation of the incident, including the amount ingested and the time of exposure, is crucial for appropriate management and follow-up care. Regular assessment of the patient's clinical status should be conducted to ensure timely intervention and to mitigate any potential complications arising from the overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children. In the event that the medication is swallowed, patients should seek medical help or contact a Poison Control Center immediately.

Additionally, healthcare providers should instruct patients to consult a doctor if they experience severe irritation while using the medication. This ensures that patients are aware of the necessary steps to take in case of adverse reactions and reinforces the importance of safety in medication use.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which are essential for identification and inventory management. It is recommended to store the product at room temperature to maintain its efficacy and stability.

To ensure safety, the product should be kept out of reach of children. In the event of accidental ingestion, it is crucial to seek medical assistance or contact a poison control center immediately. Special handling precautions should be observed to prevent any misuse or accidental exposure.

Additional Clinical Information

The route of administration for the product is topical. Clinicians should advise patients to seek medical advice if irritation becomes severe. It is also important to instruct patients to keep the product out of reach of children and to seek immediate medical assistance or contact a poison control center if the product is swallowed.

Drug Information (PDF)

This file contains official product information for Killa Acne Extra Strength 2 Pack, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)